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ABSTRAK 
Pengenalan 
Perbezaan jangka hayat pesakit leukemia akut di negara-negara maju dan negara-negara 
membangun sudah diketahui umum. Namun, kajian mengenai basil rawatan dan juga 
jangka hayat leukemia akut di kalangan kanak-kanak. yang diterbitkan oleh negara-
negara membangun termasuk Malaysia masih kurang. Sehingga sekarang, belum ada 
satu pun kajian sebegini yang diterbitkan dari Hospital USM. 
Objektif 
Objektif kajian ini adalah untuk menilai kadar jangka hayat menyeluruh (OS) dan 
jangka hayat tanpa sebarang kejadian (EFS), dan untuk mengenalpasti faktor-faktor 
jangka hayat tanpa sebarang kejadian untuk pesakit Leukaemia Lymphoblastic Akut 
(ALL) dan Leukemia Myeloid Akut (AML). 
Kaedah Kajian 
Kajian ini dijalankan secara retrospektif melibatkan kanak-kanak berumur antara bayi 
baru lahir hingga 12 tahun yang disahkan menghidap penyakit ALL dan AML serta 
menerima kemoterapi di Unit Onkologi Kanak-Kanak Hospital USM dari tahun 1990 
hingga 2010. Kanak-kanak dipilih dan dikenalpasti daripada senarai pendaftaran di unit 
onkologi dan unit rekod perubatan Hospital USM. Model Kepelbagaian Regresi Cox 
digunakan untuk meramal faktor-faktor berisiko tinggi untuk kematian atau penyakit 
berulang bagi penyakit ALL dan AML secara berasingan. 
xiii 
Keputusan 
Terdapat sebanyak 334 kanak-kanak menghidap penyakit leukemia akut ( 257 ALL dan 
77 AML) yang didaftarkan di dalam senarai pendaftaran. Sebanyak 224 kanak-kanak 
ALL dan 59 AML yang menyertai kajian, memberikan kadar penyertaan sebanyak 87% 
untuk ALL dan 77% untuk AML. Purata jangkamasa rawatan susulan adalah 73 bulan. 
Kadar jangka hayat menyeluruh (OS) untuk ALL pada 1, 3 dan 5 tahun adalah 77.7%, 
66.9% dan 63.5% dan untuk AML masing-masing 59.3%, 41.4% dan 39.1%. Kadar 
kehidupan tanpa sebarang kejadian (EFS) untuk ALL pada 1, 3 dan 5 tahun adalah 
69.6%, 54.1% dan 47.8%, manakala untuk AML masing-masing S2.0%, 40.6% dan 
38.1%. 
Analisa Multivariat menunjukkan faktor-faktor berisiko tinggi untuk ALL adalah umur 
kanak-kanak melebihi 10 tahun semasa penyakit disahkan (HR 3.6; 9S% CI: 1.9-6.7), 
dan umur antara 5 hingga 9.9 tahun (HR 1.6; 95% CI 1.1-2.4). 
Analisa yang sama untuk AML menunjukkan saiz limpa > Scm (HR 4.1; 9S% CI: 1.4-
11.1), dan protokol rawatan AML BFM-87 (HR 2.9; 95% CI: 1.3-6.3) adalah lebih 
berisiko berbanding saiz limpa ~ Scm dan protokol rawatan AML 12 UK. 
Kesimpulan 
J angka hayat untuk ALL dan AML dalam kajian ini adalah setanding dengan negara-
negara membangun tetapi masih rendah berbanding dengan negara-negara maju. Kajian 
ini juga telah dapat mengenalpasti faktor-faktor peningkatan risiko kematian dan 
penyakit berulang untuk penyakit ALL dan AML di tempat kajian. 
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ABSTRACT 
Introduction 
It is well known that there is difference in survival of children with acute leukaemia 
between developed and developing countries. However, there are lack of reports in the 
treatment outcome and the survival of children with acute leukaemia in developing 
countries including Malaysia. To date, there is no published study predicting the 
treatment outcome in Hospital USM. 
Objectives 
The objectives of this study were to evaluate the overall survival (OS) and event free 
survival (EFS) rate and to identify factors that determine the EFS of childhood Acute 
Lymphoblastic Leukaemia (ALL) and Acute Myeloid Leukaemia (AML) in Hospital 
USM. 
Methodology 
This study was a retrospective record review of children from newborn to 12 years old 
who were diagnosed with ALL and AML and received chemotherapy in Paediatric 
Oncology Unit Hospital USM from year 1990 to 2010. Children who were recruited 
were identified from registry in paediatric oncology unit and medical records in 
Hospital USM. Multiple Cox Regression model was used to predict the poor prognostic 
factors for increased risk of death or relapsed for ALL and AML separately. 
XV 
Results 
There were 334 acute leukaemia children (257 ALL and 77 AML) in the registry. Out 
of these, 224 ALL and 59 AML were enrolled, giving a response rate of 87% for ALL 
and 77% for AML. The mean duration of follow up was 73 months. The OS rate for 
ALL at 1, 3 and 5 years were 77.7%, 66.9% and 63.5% respectively and for AML were 
59.3%, 41.4% and 39.1% respectively. The EFS rate for ALL at 1, 3 and 5 years were 
69.6%, 54.1% and 47.8%, for AML were 52.0%, 40.6% and 38.1% respectively. 
Multivariate analysis showed that the independent poor prognostic factor for ALL are 
presenting age at diagnosis; age above 10 years old (HR 3.6; 95% CI: 1.9-6.7), and aged 
between 5 to 9.9 years old (HR 1.6; 95% CI: 1.1-2.4). 
Similar analysis showed that spleen size > Scm (HR 4.1; 95% CI: 1.4-11.1 ), and 
treatment protocol with AML BFM-87 (HR 2.9; 95% CI: 1.3-6.3) were independent 
poor prognostic factors for AML compared to spleen size~ Scm and AML 12 UK 
protocol. 
Conclusion 
Survival rate in this study was comparable to developing countries but remained low 
compared to developed countries. The study had also identified a few prognostic factors 
for increased risk of death and relapsed in ALL and AML for the local set up. 
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1.1 BACKGROUND 
CHAPTER ONE 
INTRODUCTION 
Hospital Universiti Sains Malaysia (Hospital USM) is the only tertiary centre for 
Paediatric Oncology in the East-Coast of Peninsular Malaysia, and is the referral centre 
for childhood malignancies for the state of Kelantan, Terengganu and Pahang. 
Paediatric Oncology Unit Hospital USM officially started in 1989. It is a 23 bedded 
ward specifically design for the treatment of oncology children. Most of the children are 
warded and treated for haematological malignancies which include acute lymphoblastic 
leukaemia (ALL) and acute myeloid leukaemia (AML). Other cases being treated in this 
ward are lymphoma and multiple solid tumours. 
The aim of this study was to evaluate the survival of childhood ALL and AML who 
received chemotherapy in Paediatric Oncology Unit Hospital USM from year 1990 to 
2010 as well as to identify the factors that determine the survival of childhood acute 
leukaemia. 
In Malaysia, only a few studies have been published on the treatment outcome of acute 
leukaemia. Ng et al. (2000) published a study regarding treatment outcome of childhood 
ALL from Hospital University Kuala Lumpur, while a similar study done in Hospital 
USM by Nik Nasiruddin et al. (2007) remained unpublished. 
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1.2 SURVIVAL 
ALL represents approximately 80% of all childhood leukaemias, followed by AML 
(15%), and CML (5%). The worldwide incidence has increased and it becomes an 
important reason for childhood mortality. Fortunately with modern treatment regime, 
the treatment responses are encouraging leading to better overall survival (OS). The OS 
and event free survival (EFS) can be looked at different time frames, such as at 1 year, 2 
years, 3 years, 5 years, 1 0 years, 15 years and 20 years. 
There are no single established criteria for the definition of OS and EFS. Review of 
other studies showed that there were various definitions of OS and EFS. OS is defined 
as the time from the diagnosis until death from any causes or until the last follow up 
(Tang et al. 2008; Yeoh et al. 2012). 
In Malaysia, EFS is defined as the interval between the date of diagnosis and the earliest 
occurrence of the following event.s: induction failure, leukaemic relapse, death from any 
cause, last contact, development of a second malignant neoplasm and bone marrow 
transplant (Ng et al., 2000). · 
Bonilla et al. (2010) in El Salvado~ defined EFS as the time from diagnosis to the first 
event such as resistant disease, ·relapse, and second malignant neoplasm, abandonment 
of treatment or death or last contact. 
In an unpublished study in Hospital USM by Nik Nasiruddin et al. (2007), EFS was 
defined as the time from initiation of therapy to the date of failure (any relapse, death or 
secondary cancer) or to the date when the patient was confirmed to be well at the time 
of recruitment, whichever occurred first. 
In France, Sirvent et al. (20 11) calculated the EFS from the date of complete remission 
until the first event (relapse, death of any cause) or until the last follow up. 
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In this study, EFS was considered t~e time from diagnosis to the date of any event or to 
the date when patient was confirmed to be well, or at the date of census, whichever 
occurred first, (the event was considered as relapse, defaultment, death or any major 
complications). 
1.2.1 Survival in Developed Countries 
In developed countries, many studies had been published regarding survival and 
treatment outcome of childhood acute leukaemia. A study conducted in France between 
the year 1990 to 2000, involving 4807 children with acute leukaemia found that the 
survival rate for ALL at 1 year was 94% (95% CI: 93, 95) and at 5 years was 82% (95% 
CI: 80, 83). On the other hand, AML survival was consistently lower than ALL, it was 
95% (95% CI: 91, 95) at 3 months and 60% (95% CI: 57, 64) at 3 years (Goubin et al., 
2006). 
There was a longer study duration completed in Italy that showed the trend of ALL 
survival in between the year 1972 to 2001. In this study, a total of 967 leukaemia 
children were recruited and out of this, 754 were children with ALL. The results 
showed that 10 years survival for ALL has improved from 86% (95% CI: 83, 88) to 
97% (95% Cl: 95, 97) for children diagnosed from 1972 to 1976 and from the year 1997 
to 2001. ALL showed stable survival rates after I 0 years following diagnosis (Zuccolo 
et al., 2006). 
The difference in improvement of survival between ALL and AML was observed in the 
European studies as well. This was supported by data collected from the Automated 
Childhood Cancer Information System (ACCIS) project from the year 1978 to 1997. 
The improvements were attributed to better intensive care treatment protocol and 
adherence to treatment, (Coebergh et al., 2006). The study also emphasized on survival 
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of 25623 children with acute leukaemia. The 5 yeCI!s survival went from 51% (95% CI: 
50, 53) in children diagnosed from 1978 to 1982, to 77% (95% CI: 76, 78) for those 
diagnosed from the year 1993 to 1997. Overall survival in North Europe for ALL was 
83% (95% CI: 80, 85), whereas for AML it was 54% (95% CI: 46, 62) 
(Coebergh et al., 2006). 
United Kingdom Childhood Cancer Study (UKCCS) reported survival rate of 1899 
children with leukaemia diagnosed from 1991 to 1996. In this report, 1573 were 
children with ALL and 326 were AML. The 5, 10 and 15 years survival rate for ALL 
were 81.1% (95% Cl: 79, 82), 75.3% (95% CI: 73, 77) and 74.2% (95% CI: 71, 76) 
respectively. Whereas for AML, 5, 10 and 15 years survival were 55.9% (95% CI: 50, 
61), 53.8% (95% CI: 47, 59) and 53.5% (95% CI: 47, 59) respectively. 
The most recent paper that was published in the Journal of Clinical Oncology in 2012 
showed that ALL survival rates had improved significantly. The study conducted by the 
University of Colorado Cancer Centre Aurora, Colorado, which included 21000 
children and more than half of the population were from the United States who were 
diagnosed from 1990 to 2005. The author found that 5 year survival rates improved 
from 83.7% to 90.4% in the year 1990 to 1994 and in the year 2000 to 2005 
respectively. The survival rates increased for boys and girls in all races and ages except 
in infants as most of the infants died due to the side effects of treatment. Furthermore, 
infant had different biological feature of leukaemia which carries poorer prognosis 
(Hunger et al., 2012). 
In a study conducted in Brazil among ALL children aged from 2 months to 89 months 
in 1995 to 2004. Total of 84 children were treated with Brazilian Group for the 
Treatment of Childhood Leukaemia Protocol with their 5 years EFS was 74.1% 
(Scrideli et al., 2006). 
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A similar study. was conducted in Czech Republic looking at surviv~l of childhood 
AML. The study enrolled 61 AML children who were treated with AML BFM 93 
Protocol. It was reported that 73.8% of them achieved complete remission, OS and EFS 
rates at 5 years were 45.3% and 42.3% respectively. As expected, the survival was 
better for standard risk group compared to high risk group with EFS of 62.5% versus 
29.7% respectively (p = 0.030) (Stary et al., 2004). 
In addition to that, a study published in the United Kingdom that was conducted from 
1995 to 2002 involving children less than 16 years old showed the 10 years OS and EFS 
to be 63% and 54% respectively (Gibson et al., 2011). 
1.2.2 Survival in Developing and Non-developed Countries 
There was a difference in terms of treatment outcome between developed and 
developing countries. The survival was found to be lower in developing countries 
compared to the developed countries (Nik Nasiruddin et al., 2007). 
In our country, there were not many studies conducted on this topic. A study done in 
University Hospital Kuala Lumpur involving 57 5 children aged 12 years old and below 
from 1980 to 1995 reported 2 years survival rate for ALL was 67% (Ng et al., 2000). 
In Hospital USM Kelantan, unpublished study by Nik N asiruddin et al. (2007) 
described the treatment outcome of children with ALL. In this study, a total of 102 ALL 
children were recruited from the year 1990 to 2003. They found that overall EFS rate 
was 81.4% (SE ± 3.9) at 1 year, 59.8% (SE ± 4.9) at 3 years, 55.3% (SE ± 5) at 5 years 
and 52% (SE ± 5.2) at 10 years. 
In a recent study conducted among Malaysian and Singaporean population from 2002 to 
2011 by using risk adapted treatment modified BFM ALL protocol. They studied 556 
5 
children aged 1 month to 18 y~ars old using minimal residual disease (MRD) as 
treatment stratification. They found that 5 and 6 years OS and EFS rate were 88% and 
80% respectively (Yeoh eta/., 2012). 
Another study carried out by Chan et al. (2004) demonstrated an increased in 5 years 
EFS rate among AML children who were treated with AML BFM 83 regimes in 
University of Malaya Medical Centre. In this study, a total of 174 paediatric children 
were enrolled from 1985 to 1999. The 5 years EFS rate for children diagnosed from 
1985 to 1993 was 30.7% and from 1993 to 1999 was 41.3% respectively. 
The increased in survival rate of childhood leukaemia was also demonstrated in a study 
published in our neighbouring country, Singapore. This study was conducted from the 
year 1988 to 1994. A total of 66 children were recruited, in which 53 children were 
ALL and 13 were AML. A two year disease free survival (time from completed 
treatment until remission or no disease) for ALL was 62% and 30% for AML 
(Quah et al., 1996). 
In addition to this, there were also a few studies in China regarding the survival of acute 
leukaemia. Tang et al. (2008) in their study from the year 1998 to 2004 involving 346 
ALL children aged less than 16 years old revealed that 5 years overall EFS rates as 
38.5%. They found high rate of abandon treatment among the children (48%). 
Another study on AML involving 185 children aged less than 16 years old from year 
1997 to 2005 found that 32% of the children refused chemotherapy. For those who were 
treated, the 5 years OS and EFS rates were 50% and 46% respectively (Xu et al., 2010). 
In conclusion, the overall findings from these studies showed improvement of survival 
rate over the years and it was higher in developed countries. Advancement in current 
6 
chemotherapy currently showed an increase in cure r~te and better survival rate in acute 
leukaemia. In all childhood malignancies, ALL achieved the most favourable prognosis. 
1.3 EPIDEMIOLOGY AND INCIDENCE 
The incidence of acute leukaemia has arisen over the years. This had been reported in 
many studies and it was largely attributed by many factors such as higher diagnostic 
awareness, changing in environment and pollutant. The increased in incidence of acute 
leukaemia was found to be irrespective of age, gender or staying in developed or 
developing countries. For ALL, the incidence was more prevalent in male compared to 
female and the most affected age group was 1 to 4 years old with peak age between 2 to 
4 years old. However, for AML the incidence was equal between both genders. The 
highest incidence occurred in those aged 1 to 4 years old with a peak incidence at 2 
years old. 
To date, there are many large studies (trials) looking at the incidence of childhood 
leukaemia according to age and gender. One such study was done in Europe between 
1978 and 1997 which involved 17065 leukaemia children aged from 0 to 14 years old. 
Majority of these children 8043 ( 4 7%) were within age group 1 to 4, 4831 (28%) age 5 
to 9, 3293 (19%) between the age 10 to 14, while only 898 (5%) belongs to age< 1 
years old (Coebergh et al., 2006). 
Another study in France which was conducted in 1990 to 2000, recruited 3995 of ALL 
children aged between 0 to 14 years old and this study also demonstrated similar 
incidence of acute leukaemia according to age group. For AML, a total number of 812 
children were recruited in the study and 132 (16%) aged less than 1 year old, 259 (32%) 
aged 1 to 4 years old, 197 (24%) aged 5 to 9 years old and 224 (28%) aged 10 to 14 
years old (Goubin et al., 2006). 
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Interestingly, a. study by Coebergh et al. in 2006 showed a male predominance in 
incidence of childhood ALL. Out of the 17065 children with ALL recruited in this 
study, 9551 (56%) were boys while 7514 (44%) were girls. 
The overall increase in rate of childhood acute leukaemia over the years was observed 
in a study conducted in Ibn Ghazwan Women and Children Hospital, Paediatric 
Oncology Ward in Basrah, Iraq between 1993 and 2007. Total of 698 leukaemia 
children were registered from 1993 to 2007, comprising the age from 0 to 14 years old. 
The incidence of acute leukaemia was increased with the rate of 2. 7 every 3 years until 
2007 (Hagopian et a/., 201 0). 
Another study conducted in Thailand between 1985 and 2002 reported that the 
incidence has increased by 2.4% per year in boys (95% CI: -0.5 to 5.3) and 4.1% per 
year in girls (95% CI: 1.1 to 7.2) (Kamsa-ard et al., 2006). 
1.4 ETIOLOGY 
The cause of acute leukaemia is multifactorial. The leukaemic transformation involves 
complex interactions within host (chromosomal damage) either through in utero gene 
abnormality or damage due to chemical exposure or infective agents. From studies 
among twins as well as neonatal blood spots, it has been possible to track the first 
initiating genetic events in fetal hematopoietic stem cells in utero for most precursors B-
cell ALL and AML. In Basrah, there are many environmental factors that have been 
implicated as the causative agents for leukaemia such as ionizing irradiation and certain 
chemicals like benzene and cytotoxics (Hagopian et a/., 201 0). 
Tim Eden, (201 0) in his article review stated that folate deficiency and alterations in 
folate metabolism resulting from polymorphic variants of the enzyme 
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methylenetetrahydrofolate reduct~se (MTHFR) had been associated with cancer, neural . 
tube defect and heart disease. Lower activity of MTHFR has been reported to be 
protective for ALL. 
A study was conducted by Malaysian and Singaporean ALL Study Group, showed the 
various genetic susceptibility to childhood ALL. In this study, cord blood sample of756 
healthy newborns (346 Chinese and 410 Malays) and blood of 531 children with ALL 
(321 Chinese and 21 0 Malays) from the year 1998 to 2008 were tested for genetic 
variability. They found that Malay population predominantly carries (Quinine 
oxyreductase) NQOl 609CT genotype. A comparison was made between gender, this 
gene showed significant protective effect on leukaemia risk in Malay boys (OR = 0.4; 
95% CI: 0.22, 0.66; p = 0.001). In the Chinese cohort, instead of NQOI 609CT 
genotype, they carry MTHFR 1298 c-allele; and this is significantly associated with 
increased risk of leukaemia among Chinese boys (OR = 1. 7; 95% CI: 1.17, 2.44; 
p = 0.005) (Y eoh et al., 201 0). 
On the other hand, several inherited genetic abnormalities has been showed as 
predisposing factor to leukaemia including Down's syndrome, Fanconi's anemia, 
Bloom syndrome and ataxia-telengiectasia. In cancer treatment review, an exposure to 
pesticide also had been found to increase risk of leukaemia (OR = 1.5; 95% CI: 1.0, 
2.2). One example was parental exposure to hydrocarbons (OR = 1.8, CI: 1.3, 2.5). 
Benzene had also been implicated as a potential leukaemogenic agent as well 
(Eden, 201 0). 
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1.5 CLINICAL FEATURES 
The clinical features of childhood acute leukaemia are mainly attributed by ineffective 
haematopoiesis. Thus, it results in anaemia, thrombocytopenia, abnormal white cell, 
infiltration of leukemic cell into organs and constitutional symptoms. In general, the 
presentation for ALL and AML could be similar. The usual presentations for this 
childhood malignancy are pallor and lethargic, prolonged fever, bruises or bleeding 
tendency. Disseminated intravascular coagulopathy (DIVC) might be observed at initial 
presentation of AML especially in acute promyelocytic leukaemia (APL). Other 
features are due to organ infiltration by leukaemic cells such as hepatosplenomegaly, 
lymphadenopathy, testicular swelling, arthritis, acute renal failure, meningeal syndrome 
(features of increase ICP, papilloedema, retinal haemorrhage) or anterior mediastinal 
mass (T-ALL) and chloromatous tumour (AML). 
1.6 DIAGNOSIS 
The presence of blast cell in peripheral blood film is suggestive of leukaemia. However, 
gold standard for the diagnosis is by morphological F AB criteria and cytochemistry 
analyses with > 25% of blast cells present in BMA. 
1.7 CLASSIFICATION 
1. 7.1 Classification of ALL 
Blast cells are the leukemic cells. There are two methods of classification of this 
disease. The best classification is the F AB classification (French-American-British) 
which is based on the morphological of the cell. This classification subdivided ALL into 
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3 subgroups: . 
i) Ll :small lymphoblast, little cytoplasm (good prognosis) 
ii) L2 : larger and pleomorphic lymphoblast, more cytoplasm 
iii) L3 : large lymphoblast, cytoplasmic vacuoles, fine stippled nuclear chromatin 
This classification has a prognostic value. The L 1 subtype is more frequent in younger 
children, whereas L3 is more common in older children. The L1 subtype is associated 
with good prognosis (Schrappe et al., 2000). 
The other classification is based on immunophenotypes classification, which can be 
divided into B-lineage and T -lineage cells. It is based on the differentiation stages of 
lymphoid progenitors during haematopoiesis (Plasschaert et al. 2004). 
European Group for the immunological characterization of Leukaemia (EGIL) 
classified ALL into B-cell, T-cell or biphenotypic acute leukaemia (mixed type). B 
lineage markers are CD 10, CD 19, CD 22 and CD 79a, whereas T -cell markers are CD 
la, CD 2, CD 3, CD 4, CD 5, CD 7, and CD 8. All of the B-cell and T-cell can 
additionally express myeloid antigens or stem-cell antigen CD 34. Biphenotypic acute 
leukaemia (BAL) is a rare lineage and it co-expresses markers of two different lineages. 
It is defined when scores are more than 2 for myeloid lineage and more than 1 for the 
lymphoid lineage. It also shows much higher incidence of CD 34 antigen expression, 
extramedullary infiltration, relapse and resistance to therapy after relapse. 
1. 7.2 Classification of AML 
For AML classification, two systems have been used; The French American British 
(FAB) classification and newer World Health Organization (WHO) classification. 
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The older FAB system divides .{\ML into subtypes, based on the type of cell involve~ 
and the stage of maturation. It is classified mainly based on morphology using 
cytochemical stains. There are eight subtypes of AML; from MO to M7, (as shown in 
Table 1). 
The WHO classification system looks into several broad groups, cytogenetics and early 
response to treatment and it will take into account the prognostic factors, (as shown in 
Table 2) (Gertjan eta/., 2007). 
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Table 1: F AB Classification of AML 
F AB Classification of AML 
MO This subtype of AML is made up of very immature cells. This type of 
cells can be distinguished from ALL by flow cytometry. It is very rare in 
paediatric age group. 
Ml This subtype is made up of immature myeloblasts. It can be recognized by 
the way the cells look under the microscope by using cytochemical stains. 
M2 This subtype is composed of slightly more mature form of myeloblasts. It 
is the most common AML subtype in children. 
M3 It also known as APL; it is made up of promyelocytes, which are more 
mature forms of myeloblasts. Treatment of APL is different from other 
subtypes of AML, as it prone to have DIVC. 
M4 This is also known as acute myelomonocytic leukaemia. The cells are 
early form of monoblast. It is more common in children less than two 
M5 years old. 
It is known as acute monocytic leukaemia and made up of monoblasts. 
Like M4 subtypes, it is more common in children younger than 2 years of 
age. 
M6 This subtype is known as acute erythroblastic leukaemia. It starts in 
erythroblasts, the cells that normally mature into red blood cells. It is very 
rare in paediatric. 
M7 This is known as acute megakaryoblastic leukaemia. The cells are 
megakaryoblasts, which nonnally mature into megakaryocytes (the cells 
that make platelets). 
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Table 2: WHO Classification of AML 
WHO Classification of AML 
AML with recurrent AML with t(8;12)(q22;q22), AMLI(CBF-a)/ETO 
cytogenetic translocations Acute promylocytic leukaemia 
AML with t(15; 17) and variant; PMLIRARa 
AML with abnormal bone marrow eusinophils 
AML with 11 q23 (MLL gene) abnormalities 
AML with multilineage With prior myelodysplastic syndrome 
dysplasia Without prior myelodysplastic syndrome 
AML with myelodysplactic Alkylating agent related 
syndrome, therapy related Epipodophyllotoxin related 
Other types 
AML not otherwise AML minimally differentiated 
categorized AML without maturation 
AML with maturation 
Acute myelomonocytic leukaemia 
Acute monocytic leukaemia 
Acute eryhtroid leukaemia 
Acute megakaryocytic leukaemia 
Acute basophilic leukaemia 
Acute panmyelosis with myelofibrosis 
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1.8 PROGNOSTIC FACTORS 
1.8.1 Prognostic Factors for ALL 
Few prognostic factors had been identified for childhood ALL. The risk of relapse 
mostly depends on the risk factor themselves. Different institutions applied prognostic 
factor differently to define risk categories, based on differences in biologic and 
socioeconomic background. Biologic variables included demographic features such as 
age and sex, disease related features such as initial TWC, uric acid level, DNA index, 
immunophenotype, presence of mediastinal mass at diagnosis and CNS status. 
Risk category is further divided into standard risk (SR) or high risk (HR). SR is defined 
when age at presentation is between 1 to 10 years old, initial TWC < 50 x 109/L, 
absence of high risk features such as CNS and testicular involvement, T cell 
immunophenotype, M3 marrow on D15 or M2/ M3 marrow on D36 and DNA index 
1.16 to 1.6 (Bonilla et al., 2010). M2 marrow is defined as the presence of 5 to 25% of 
blast cells in bone marrow (partial remission) while M3 marrow is defined as the 
presence of more than 25% blast cells in bone marrow (not in remission). 
Age at diagnosis is one of the prognostic factors for ALL. Infants and children older 
than 10 years old have poorer prognosis and this had been shown in many previous 
studies. In France, 5 years EFS rate was 87% (95% CI: 85, 88) for children aged 1 to 4 
years, followed by children 5 to 9 years old with EFS rate of 83% (95% CI: 81, 85). The 
5 years EFS for children aged 10 to 14 years was 72% (95% Cl: 69, 76) and infant less 
than 1 year old was only 48% (95% CI: 39, 57), it was statistically significant 
(p = 0.001) (Goubin et al., 2006). 
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A similar pattern was seen in a recent study in ~e United Kingdom by Lightfoot et al. 
(20 12) involving 1559 ALL children less than 14 years old. Five years EFS rate were 
85%, 80%, 70% and 45% in children age 1 to 5, 6 to 9, more than 9 years and less than 
1 year old respectively. Another study conducted in Pakistan showed children aged I to 
9 years old had a better outcome compared to infants< I year or children> 10 years old 
(p < 0.040) (Khalid et al., 20IO). 
Another prognostic factor for ALL is gender. Previous studies have shown that female 
have better outcome compared to male, and this differences appeared after 2 to 3 years 
old. In France a study was carried out by Goubin et al. (2006) showed that 5 years EFS 
rate in female was 83% (95% CI: 81, 85) and 81% (95% CI: 79, 82) in male, however 
the statistically insignificant (p = 0.070). This finding is similarly shown in a study in 
United Kingdom involving 1573 children aged 0 to 14 years old from 1991 to 1996. 
They found 5 years EFS rate in female as 82.6% and in male as 79.8% (p = 0.024) 
(Johnston et al., 20I 0). 
In Malaysia, Ng et al. (2000) found that 5 years EFS rate in male was 70% while in 
female it was 75% (p = 0.1 00). Another study in India revealed gender had a significant 
influence on the outcome of survival with a higher failure rate in boys (p = 0.003), 
(Kulkani et al., 2004 ). They postulated that this was due to the testes acting as a 
'sanctuary site' and blood testes barrier protected the leukemic cells from the anticancer 
drugs. This may be due to lack of stratification of treatment and hence high risk patient 
may have been under treated. 
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Majority of_ children with malignancies live in lower socioecono~ic country or come 
from lower socioeconomic background (Bonilla et al., 201 0). The cure rate of ALL is 
higher in developed compared to developing countries. A few contributing factors have 
been identified such as lower educational background, lack of knowledge about the 
disease as well as effect of the treatment. Therefore, they are prone to default or 
abandon the treatment and this subsequently will lead to relapse. 
A study done in El Selvador, a low socioeconomic country from the year 2000 to 2007 
looked at the predictors of EFS in children with ALL from lower income countries. 
There were 443 with 260 children in standard risk and 180 children in high risk group. 
Five years EFS was 56% (SE ± 4.5) for standard risk group and 48.6% (SE ± 5.5) for 
high risk group. The 5 years OS rate was 77.7% (SE ± 3 .8) for standard risk and 61.9% 
(SE ± 5.8) for high risk group. Parental educational level was measured in relation to 
the treatment outcome and the findings from this study suggest that parental secondary 
education gives better outcome compared to the illiterate and primary education level 
(HR 0.49; 95% CI: 0.29, 0.84; p < 0.001). This was mainly due to better treatment 
adherence in this group. Apart from socioeconomic status, other useful predictors of 
EFS include the level of income, number of siblings and nutritional status among these 
children (Bonilla et al., 2010). 
Treatment outcome associated with high total white cell count (TWC) at diagnosis has 
been proven as a risk factor for relapse. This represents a significant tumour burden. 
A local published study by Ng et al. (2000) showed that high TWC and low 
haemoglobin level were significantly related to poorer prognosis. Out of 567 children, 
126 of them had TWC above 50 x 103/JJL at presentation and 70 children with high 
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TWC had failure rate (lack of response to induction therapy, relapsed during fi~st 
complete remission or death due to any causes), (p = 0.003). 
In a Brazillian study, total of 84 ALL children involved, 59 children with TWC < 50 x 
HP/J.lL had 5 years EFS rate of79.3%, compared to 25 children with TWC >50 103/J.lL 
had 5 years EFS rate of 62.0% (p = 0.030) (Scrideli et al., 2006). A similar outcome in 
children presented with TWC of more than 100 x 103/J.lL, it was highly associated with 
CNS relapse rate (HR 2.9; p = 0.002) (Sirvent et al., 2011). 
In another study using multivariate analysis among Indian children showed that high 
TWC was a significant predictor for relapse {p= 0.001) (Kulkarni et al., 2009). 
Other than TWC at presentation, the size of liver and spleen also provide the 
measurement of leukemic cell burden. The size of liver or spleen (more than 3 to 5 em), 
it has a positive correlation as poor prognostic factors (Ng et al., 2000). 
Hepatosplenomegaly was present in about 50 to 65% of childhood ALL (Plasschaert et 
al., 2004). A large study completed in United States involving 8447 childhood ALL 
from year 1983 to 1995. They found that children with splenomegaly had a relative risk 
of relapse of 1.3 times (95% CI: 1.2, 1.4) while children with hepatomegaly had a 
relative risk of relapse of 1.1 times (95% CI: 0.9, 1.2) (Bhatia et al., 2002). 
ALL is classified based on differentiation stages of development T -lineage and B-
lineage lymphoid progenitors. T -cell immunophenotype has poorer prognosis even 
though it is less common compared to B-cell ALL as T -cell was associated with high 
TWC at presentation, mediastinal mass and it occurs in older children. Children who did 
not go into remission were in the older age group, diagnosed with T -cell ALL, and this 
result is statistically significant (p = 0.020) (Sazawal et al., 2001 ). 
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Supriyadi et al. (2012) conducted a study in ~donesia involving 239 ALL children 
from year 2006 to 2011. They were treated with Indonesian 2006 Protocol. Seventy 
seven percent of them were B-celllineage and 23% were T-celllineage. Majority ofT-
cell children were in high risk group with TWC more than 50 x 103/J.lL. Children with 
T -cell lineage with myeloid expression had significant higher adverse prognostic factors 
compared to myeloid negative (p = 0.028). Three years EFS rate was 40% in myeloid 
positive compared to 77% in myeloid negative. B-cell lineage carried good prognosis 
because it was associated with lower TWC. 
CNS infiltration or meningeal leukaemia is one of the frequent manifestations of 
extramedullary leukaemia. Children may present with signs and symptoms of increased 
in intracranial pressure such as vomiting, headache, blurring of vision, seizure or 
neurological deficit. CNS infiltration at diagnosis is known to be one of the poor 
prognostic factor and children must be stratified in high risk group. 
CNS infiltration is defined as finding of more than 5 cell/ uL 60 in cytocentrifuge CSF 
blast cell (Plaschaert et al., 2004). It is divided into CNS 1, CNS 2 and CNS 3. 
CNS 1 is defined as less than 5 WBCs/uL with no CSF blast cells. CNS 2 is when there 
is less than 5 WBCs/uL with CSF blast cells and CNS 3 is presence of 5 or more 
WBCs/uL with the presence of CSF blast cells or cranial nerve palsy. 
Ng et al., 2000 showed among Malaysian population, CNS involvement at diagnosis 
was 2% (Ng et al., 2000). 
Similar finding by Plaschaert who described in Netherland population, the CNS 
involvement was about 2.6 to 3.6% (Plaschaert et al., 2004). 
Kulkarni et al. (2004) concluded in their study that there was high incidence of relapse 
especially CNS due to more children with high risk group compared to developed 
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country. 'I}leir 5 year survival rate in CNS involvement was 3~.7% whereas in non 
CNS involvement was 72%. 
In EORTC Children Leukaemia Group study, they conducted a study on survival rate in 
children with initial CSF involvement treated without cranial irradiation. This study 
involved ALL children aged less than 18 years from year 1989 to 1998 in France, 
Belgium and Portugal. They found that OS rate among children with CNS 1 at 8 years 
was 80.9% (SE ± 0.9) whereas in children with CNS 3 was 67.4% (SE ± 6.8) (Sirvent et 
a/., 2011). The evidence support the need for additional CNS directed therapy, 
intrathecal and radiotherapy and prophylactic CNS therapy to increase survival rate. 
Relapse of disease is known to be one of the major events in acute leukaemia. It is a 
major complication which caused mortality and morbidity. Relapse can occur at many 
sites and majority occurred in the BM followed by CNS, testis or combination. An 
Indian study showed typical pattern of relapsed in childhood ALL. The study found 
24% (n = 127/532) of their children developed relapse. Majority of relapse occurred 
while children were still on chemotherapy. Bone marrow relapse occurred in 40.8% 
(n = 51) and CNS relapse in 18.9% (n = 24). Isolated testicular relapse were seen in 
15.3% (n = 17/111). Significant predictors for relapse were male gender (p = 0.030) and 
high TWC at presentation (p = 0.001) (Kulkarni et al., 2009). 
In recent paper published by Y eoh et al. (2012), out of 556 children, 6% (n=36) 
children developed relapse and 61% of them had isolated BM relapse. 
Early treatment response to steroid also give significant prognostication for childhood 
ALL. It indicates the rate of clearance of leukaemic cells from the blood or BM during 
early phase of therapy. Each centre has different definition of early response. Good 
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early response is defined as TWC in FBP at day 8 of induction with steroid of less ~an 
1 000/ JlL or absence of blast, whereas poor early response is defined as presence of 
TWC in FBP more than 1000/ JlL or still presence of blast cells at day 8 of induction 
with steroid. Undetermined early response is defined when there was uncertainty of 
blast cells in FBP at day 8 of induction. Uncertainty of blast is described by 
haematologist as 'suspicious cells'. Five years EFS of good early response was 82.8% 
(SE ± 0.9) compared to poor early response was only 34.3% (SE ± 3.4) (Schrappe et al., 
2000). 
Some other centres used the definition of good early response as blast cells less than 
25% in BM at Day 7 of four chemotherapy agents during induction therapy or blast 
cells less than 1000/ J.1L in FBP after 7 days of initial prednisolone therapy, or less than 
25% of blast cells in BM at day 14 following three chemotherapy agents during 
induction therapy (Sackmann-Muriel et al., 1999). 
In Malaysia, Jiang et al. (2011) defined good prednisolone response as children with 
less than 1000/ J.1L peripheral blast after 7 days of prednisolone and poor prednisolone 
response when peripheral blast counts more than 1000/ J.1L after 7 days of prednisolone 
therapy. This study involved 472 children, 422 children who had good response to 
steroid and the rest of 50 children had prednisolone poor response. They found 
significantly lower EFS rate in prednisolone poor response group (p = 0.001). Another 
study by Yeoh et al. (2012) documented prednisolone response status from 4 hospitals 
in Malaysia and Singapore, their 6 years EFS rate were 63% and 83% in children with 
poor prednisolone response and good prednisolone response group respectively. 
In Indonesia, a study looking at early response to dexamethasone as a prognostic factor 
for ALL was carried out as well. They have involved 165 children aged less than 14 
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years old from 1999 to 2006. Out of 165 c~ildren , 133 of them with good early 
response had 26.3% (SE ± 3.8) 5 years EFS rate compared to 33 children with poor 
early response had 9.7% (SE ± 5.3) 5 years EFS rate (p < 0.001). The HR for poor early 
response was 1.9 times (95% CI: 1.25, 1.91) with statistically significant (p = 0.030) 
(Widjajanto et al., 2012). 
L-asparaginase is an effective anticancer drug. The outcome of paediatric ALL has 
improved dramatically over 40 years through a large trial including the use of 
asparaginase. It has been used for the past 30 years. The drug has improved EFS rate in 
children with ALL when given during the induction and maintenance phase. A 
paediatric study in relapsed ALL using pegaspargase showed patient with lower serum 
asparaginase enzyme activity did not achieve complete remission (Dan Douer, 2008). 
Asparaginase acts as a bacterial enzyme that catalyzed the hydrolysis of asparagine to 
Aspartic acid. Depletion in asparagine from the serum leads to inhibition of protein 
synthesis and subsequently causing apoptotic cell death of leukemic cells. There are 3 
forms of preparation as shown in Table 3. 
Asparaginase has a distinct toxicity profile. The side effects range from 
hypersensitivity, hyperglycaemia, hepatocellular dysfunction, neurotoxicity and 
pancreatitis (Narta et al., 2007). The most common side effect is hypersensitivity 
reaction manifested as urticaria, local erythema, indurations, skin rashes and 
anaphylaxis. Mild reaction can be treated with anti-histamine but in severe form, the 
drug needs to be terminated. If the reaction is moderate, the children will be subjected to 
rapid desensitization programme. 
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There wa~ a study done in Ankara, Turkey from 2004 to 2008. involving 19 children 
with systemic anaphylactic reaction. Prior to intravenous E.coli asparaginase, the 
children were given premedication using systemic corticosteroid and antihistamine I 
hour before asparaginase. Subsequently intravenous E.coli asparaginase will be 
administered 1 IU and it was doubled every 10 minutes until desired total dose was 
reached. The medication was discontinued if children developed anaphylactic reaction 
(Soyer et al., 2008) 
A National Cancer Institute Common Toxicity Criteria {CTC) graded the 
hypersensitivity reaction ranging from 0 to 4. Grade 0 is no reaction, grade 1 is mild 
local skin induration or oedema less than 10 em, grade 2 is urticaria, grade 3 is when the 
children have severe local reaction of more than I 0 em with bronchospasm and grade 4 
when the children developed systemic anaphylaxis which can lead to death. 
Table 3: Types of preparation of asparaginase 
Form of asparaginase Notes Half-life( days)-
IM administration 
E. coli Original form, can induce 1.28 ± 0.35 
hypersensitivity reactions 
Erwinia Minimal cross-reactivity with 0.65 ± 0.13 
E. coli preparation 
Pegylated E. coli Decrease immunogenicity 5.73 ± 3.24 
(pegaspargase or PEG) 
Other than that, treatment response is one of the prognostic factor for childhood ALL. 
There were many techniques to detect early treatment response in childhood ALL, 
especially in developed countries. The clearance of leukemic cells from the blood or 
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BM is an independent prognostic factor for ALL. Previously, detection of fi?.inimal 
residual disease (MRD) has been performed based on morphological findings. However 
since 1990's, MRD can be detected using PCR. 
With advanced molecular technique such as PCR for measurement of leukemic cells in 
BM, this may explain the MRD. MRD has been a powerful tool for assessing relapse in 
ALL and it becomes a risk factor for relapse (Sawada et al., 2009). The study 
considered negative MRD if level of blast cells in the BM < 1.5 x I o-4 • The relative 
risk of relapse in children with MRD compared to children with absent residual disease 
was almost 6 times. In the absence of MRD determination, good early treatment 
response is defined as the absence of blast in peripheral blood film at D8 of induction 
(Schrappe et al., 2000), or blast cells < 5% in bone marrow at D 15 of induction. 
Looking at the genetic aspect, both chromosome number (ploidy) and structural 
abnormality have a powerful prognostic indicator for the treatment outcome. The 
number of chromosome in leukemic clone is subdivided into high hyperploids (more 
than 50 chromosomes), low hyperploids with 47-50 chromosomes, pseudodiploid in 
which 46 chromosomes with structural abnormality, diploid (normal46 chromosomes), 
and hypodiploid with less than 46 chromosome (Plasschaert et al., 2004). High 
hyperploids are associated with good risk factors such as low TWC and common type 
of ALL. Incidence of high hyperploids in children was 20-32%, whereas adult was 
about 5-12%. Hypodiploidy had poor prognosis and they were stratified in high risk 
group. There were 2-4% of children with B-cell ALL had t (9, 22) translocation; 
Philadelphia and 1-2% had t ( 4, 11) translocation. Both were associated with poor 
outcome. Children with t ( 4, 11) translocation has is the worst prognosis. Translocation 
t ( 12, 21) is the most common genetic lesion in childhood ALL that is associated with 
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